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Abstract
MicroRNAs play a crucial role in the regulation of cell growth
and differentiation. Mice with genetic deletion of miR-375
exhibit impaired glycemic control due to decreased β-cell
and increased α-cell mass and function. The relative impor-
tance of these processes for the overall phenotype of miR-
375KO mice is unknown. Here, we show that mice overex-
pressing miR-375 exhibit normal β-cell mass and function.
Selective re-expression of miR-375 in β-cells of miR-
375KO mice normalizes both, α- and β-cell phenotypes as
well as glucose metabolism. Using this model, we also ana-
lyzed the contribution of β-cells to the total plasma miR-375
levels. Only a small proportion (≈1 %) of circulating miR-375
originates from β-cells. Furthermore, acute and profound β-
cell destruction is sufficient to detect elevations of miR-375
levels in the blood. These findings are supported by higher
miR-375 levels in the circulation of type 1 diabetes (T1D)
subjects but not mature onset diabetes of the young
(MODY) and type 2 diabetes (T2D) patients. Together, our
data support an essential role for miR-375 in the maintenance
of β-cell mass and provide in vivo evidence for release of
miRNAs from pancreatic β-cells. The small contribution of
β-cells to total plasma miR-375 levels make this miRNA an
unlikely biomarker for β-cell function but suggests a utility
for the detection of acute β-cell death for autoimmune
diabetes.
Key messages
& Overexpression of miR-375 in β-cells does not influence
β-cell mass and function.
& Increasedα-cell mass in miR-375KO arises secondarily to
loss of miR-375 in β-cells.
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& Only a small proportion of circulating miR-375 levels
originates from β-cells.
& Acute β-cell destruction results in measurable increases of
miR-375 in the blood.
& Circulating miR-375 levels are not a biomarker for pan-
creatic β-cell function.
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Introduction
Pancreatic α- and β-cells are the main cell types regulating
glucose metabolism through the secretion of glucagon and
insulin, respectively. In adult mice, β-cell mass is mostly de-
termined through a delicate balance betweenβ-cell replication
and apoptosis. Maintenance of proper β-cell mass is required
for maintaining glucose homeostasis, and an inability to renew
pancreatic β-cell mass results in the development of diabetes.
Autoimmune destruction of insulin-producing cells underlies
the pathophysiology of type 1 diabetes (T1D) [1], whereas
chronic metabolic stress linked to obesity and insulin resis-
tance results in a gradual impairment of pancreatic function,
demise ofβ-cells, and ultimately causes type 2 diabetes (T2D)
[2, 3]. Many regenerative therapeutic strategies have been
envisaged to increase β-cell mass or delay its decline in
T1D and T2D patients; however, most of these interventions
showed poor efficacy [4].
miRNAs are a class of small regulatory RNAs that repress
the expression of selected target mRNAs and confer robust-
ness and stability to biological networks in physiological and
pathological conditions [5]. How post-transcriptional regula-
tion by miRNAs impinges on the regulation of islet endocrine
cell mass still remains to be completely understood. miR-375
represents the most highly transcribed miRNA gene in β-cells
with significant expression in other endocrine organs such as
the pituitary, adrenal glands, skin, and intestine [6–9]. Global
miR-375 gene inactivation in mice leads to overt diabetes due
in part to decreased β-cell mass [10]. Several negative regu-
lators of cell growth are induced in miR-375KO islets and
underlie the anti-proliferative effects in pancreatic β-cells.
The importance of miR-375 in obesity-induced β-cell mass
expansion was demonstrated in miR-375 and leptin double
deficient (miR-375KO; ob/ob) mice, which exhibit impaired
β-cell proliferation and profoundly impaired compensatoryβ-
cell hypertrophy [10]. Noteworthy is the increasedα-cell mass
and circulating glucagon levels found in miR-375KO mice,
which induce augmented hepatic glucose production and, to-
gether with the decreased β-cell function, further exacerbates
glycemic control [10]. However, the relative importance of α-
and β-cell defects in the diabetic phenotype of global miR-
375KO mice still remains to be determined.
In recent years, miRNAs have been detected in extracellu-
lar fluids, including blood, saliva, breast milk, and other body
secretions [11, 12]. miRNAs are secreted by cells via
exosomes and travel in the circulation attached to high-
density lipoprotein particles, where they can be taken up by
recipient cells cultured in vitro through receptor-mediated en-
docytosis [13, 14]. Alternative routes of miRNA secretion
through microvesicles have also been described [15, 16].
Several studies have suggested that they may serve as serum
biomarkers because of their remarkable stability in blood and
characteristic expression in different tissues and disease states
[17]. miR-375 has been shown to be increased in the plasma
of two murine models with profound pancreatic β-cell death,
NOD, and streptozotocin (STZ)-treated mice [18]. However,
whether circulating miR-375 levels derive from β-cells in
these models and if miR-375 levels are modulated in diabetes
remains to be determined.
To further dissect the role of miR-375 gene dosage in the
regulation of pancreatic endocrine cell mass and glucose me-
tabolism, we generated and characterized transgenic mice
overexpressing miR-375 selectively in pancreatic β-cells
(named “Tg375”). This model was used to rescue miR-375
expression in pancreatic β-cells of global miR-375KO ani-
mals and to investigate miR-375’s specific role in the mainte-
nance of β-cell function and regulation of blood glucose ho-
meostasis in vivo. Furthermore, we used these mice to deter-
mine the overall contribution of β-cells to steady state plasma
miR-375 levels and contrast these to levels measured in dif-
ferent types of murine and human diabetes.
Materials and methods
Experimental animals
Animal models were housed in a pathogen-free animal facility
at the Institute of Molecular Systems Biology, ETHZ. The
animals were maintained on a 12-hr light/dark cycle and fed
a standard rodent chow. All animal experiments were ap-
proved by the kantonale Veterinäramt Zürich. miR-375KO
mice were maintained on a pure C57BL/6N background and
described previously [10].
Generation of miR-375 transgenic mice
Transgenic mice expressing miR-375 under the regulation of
the rat insulin promoter (RIP) were generated by inserting a
141-bp fragment encompassing the genomic murine pre-miR-
375 sequence into KpnI and HindII sites of pCRII-RIP gener-
ating pCRII-RIP-miR-375. A 1.1-kb DNA fragment generat-
ed upon digestion of pCRII0-RIP-miR-375 withNsiI and con-
taining the pRIP-miR-375 transgene was injected into male
pronuclei of C57BL/6N zygotes to generate “Tg375”
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transgenic mice. Two transgenic founder lines, designated as
B6N-Tg(Rip-375)416; 417Biat, were characterized and
displayed similar expression levels of miR-375 and metabolic
phenotypes. All mice were maintained on a pure C57BL/6N
background. Tg375 mice were genotyped using the following
primers: 5′-GCAAGCAGGTATGTACTCTCCAG-3′ and 5′-
AACGCTCAGGTCCGGTTT GTGCGAG-3′.
Intraperitoneal glucose, insulin, and pyruvate tolerance
tests
Blood glucose was measured using a Contour glucometer
(Bayer). For intraperitoneal glucose tolerance tests (IPGTT),
overnight fasted (13 h) mice were injected with D-glucose
solution at 2 g/kg. For insulin tolerance tests (ITT), animals
were injected with 0.75 U/kg body weight of a 5×10−2 U/ml
insulin solution after a 6-h fasting period. For intraperitoneal
pyruvate tolerance test (PTT), mice were injected with 2 g/kg
in overnight fasted mice. Blood glucose was measured using a
Contour glucometer (Bayer), insulin was measured by ELISA
(Chrystal Chem), and glucagon levels were determined by
EIA (Phoenix Pharmaceuticals). Streptozotocin was prepared
in 100 mM sodium citrate pH 4.5 at a concentration of
7.5 mg/ml and administered once i.p. in 5-h fasted mice at a
dose of 150 mg/kg.
Islet secretion assays
Islet secretion studies were performed on size-matched islets
following collagenase digestion and overnight culture in a
RPMI 1640 medium, 5.5 mM glucose supplemented with
10 % heat-inactivated FBS, 2 mM L glutamine, 100 IU/ml
penicillin, and 100 μg/ml streptomycin. Islet were incubated
in Dulbecco’s PBS-Hepes-BSA buffer containing 1 mM glu-
cose for 1 h before being transferred to Dulbecco’s buffer
containing 3.3 and 16.7 mM glucose solutions for 30 min
for static incubations.
Morphometric analysis and miRNA FISH
Pancreata were fixed in 4 % paraformaldehyde and embedded
in paraffin before sectioning to a thickness of 8 μm. For islet
α- and β-cell mass analysis, five sections at least 180 μm
apart were taken from each mouse (at least three mice per
group), processed in immunofluorescence with anti-insulin
(Sigma) and anti-glucagon antibodies (Millipore), and coun-
terstained with DAPI. Pancreatic sections were scanned en-
tirely using a 10× objective of a Zeiss AxioVert 200 micro-
scope, and the images were recorded and assembled by
AxionVision 4.6.3 software. The fraction of the insulin or
glucagon positive areas were determined using NIH ImageJ
software (http://rsbweb.nih.gov/ij/download), and finally, the
mass was calculated by multiplying this fraction by the initial
pancreatic wet weight. miRNA fluorescence in situ
hybridization (FISH) was performed as described previously
[19]. The miR-375 probe was synthesized with a linker that
enabled conjugation of six biotin moieties: 5′-AGCC
GaaCGaAcaaA-(L)3-B-L-B-L-B-L-B-N-B-(B-CPG),
where uppercase letters indicate DNA nucleotides, lowercase
letters indicate LNA modification, L represents spacer 18
(GlenResearch, catalog no. 10-1918-02), B represents
protected biotinLC serinol (GlenResearch, catalog no. 10-
1995-02), and B-CPG represents 3′-protected biotinLC serinol
CPG (GlenResearch, catalog no. 20-2995-10).
RNA isolation and miRNA quantification in plasma
RNAwas isolated from pancreatic islets using Trizol reagent
(Invitrogen) according to the manufacturer’s protocol. RNA
was subjected to DNaseI treatment with the DNA-free kit
(Invitrogen). RNA was reverse transcribed using a High
Capacity cDNA Reverse Transcription kit (Applied
Biosystems). Quantitative PCR was performed by Roche
384 real-time PCR machine and using Light Cycler® 480
SYBR Green Master (Roche). miRNA levels were measured
using the TaqMan microRNA Assays (Applied Biosystems),
and the results were normalized to U6 RNA. Circulating and
islet supernatant miRNA levels were determined using a
spike-in protocol and the data analyzed as described in [20].
Briefly, 240 ng of the carrier MS2 RNA and 25 pmol of
Caenorhabditis elegans miR-39 were spiked in Trizol before
addition to each sample (50 μl plasma, 200 μl supernatant of
cultured islets) and subjected to chloroform extraction and
RNA isolation using the miRNeasy isolation kit (Qiagen).
RNA was recovered in 30 μl of distillated water, and 3 μl
was used in the reverse transcription reactions. Absolute
miRNA quantification was performed by reverse transcription
of serial dilutions of synthetic oligonucleotides with sequence
to mature mmu-miR-375 (5′-UUUGUUCGUUCGGCUCGC
GUGA-3′), mmu-miR-16 (5′-UAGCAGCACGUAAAUA
UUGGCG-3′), and mmu-miR-194 (5′-UGUAACAGCAAC
UCCAUGUGGA-3′).
Patient information
Subjects were recruited from the UK and Poland with in-
formed consent prior to their inclusion in the study and ap-
proved by the ethics committee. UK subjects comprised sub-
jects with HNF1α-MODY3 (n=45), T1D (n=38), T2D (n=
58), and no diagnosed metabolic disease or healthy controls
(n=51). Subjects with T1D or T2D were selected from the
Young Diabetes in Oxford (YDX) study comprising individ-
uals diagnosed with diabetes at ≤45 years of age. T2D was
defined as follows: C-peptide positive, no requirement for
permanent insulin within 3 months of diagnosis, absence of
glutamic acid decarboxylase (GAD) antibodies. T1D was
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defined as a permanent insulin treatment since diagnosis, with
evidence of severe β-cell dysfunction (C-peptide≤0.2 nmol/l)
and/or positive GAD antibodies (>14 WHO units/ml).
Controls were normoglycaemic individuals aged 30–50 years
from the Oxford Biobank. Clinical features of HNF1α and
T2D subjects are found in Supplementary Table 1. Both
groups of diabetics were on glucose-lowering treatment.
Statistical analysis
Numerical values are reported as mean±s.e.m. Unpaired
Student’s t test was used for comparisons with two groups
and ANOVA with Bonferroni post-test for comparisons of
three or more groups. A p value <0.05 was considered as
significant.
Results
Transgenic mice overexpressing miR-375 in β-cells
have normal glucose tolerance
To further characterize theβ-cell growth promoting activity of
miR-375, we generated transgenic miR-375 mice in which the
pre-miR-375 was cloned downstream of the insulin promoter
(referred to as Tg375). Two founder lines were derived from
pronuclei microinjections, and both lines displayed ≈2-fold
overexpression of miR-375 in pancreatic islets, without “leak-
age” in other organs such lung, spleen, muscle, colon, kidney,
or heart, except minor escape in the brain, consistent with
leakage of the insulin promoter in selected hypothalamic neu-
rons (Fig. 1a). We confirmed that expression of validated
mRNA targets of miR-375 such as Gphn, Chsys, Insig2,
Mtpn, and Eef1e1 were downregulated in Tg375 islets
(Fig. 1b) [10]. Surprisingly, metabolic characterization of
Tg375 did not reveal significant changes in weight, blood
glucose, glucose tolerance, or pancreatic endocrine function
as compared to control littermate mice (Figs. 1c–f, 3, and 4).
These results indicate that increased miR-375 gene dosage in
pancreatic β-cells of mice does not alter pancreatic endocrine
cell composition and glucose tolerance.
Selective re-expression of miR-375 in β-cells
of miR-375KO mice restores normal glycemic control
To investigate the specific role of miR-375 in pancreatic β-
cells for the metabolic impairment in the global miR-375KO
mice, we crossed Tg375 mice with miR-375KO animals in
order to re-constitute miR-375 expression selectively in β-
cells, while leaving other islet endocrine cells and organs de-
pleted of the miRNA (Tg375/mir-375KO mice are referred to
as “β-Rescue”mice). Quantitative PCR (qPCR) indicated that
expression of miR-375 was recovered to ≈85 % of wildtype
(WT) in β-Rescue islets (Fig. 2a). To further validate the se-
lective reconstitution of miR-375 levels in β-Rescue mice, we
measured mRNA levels of HuD, encoding an RNA-binding
protein that regulates translation of the insulin2 mRNA [21]
and an evolutionarily conserved and experimentally validated
miR-375 target in β-cells [10]. This analysis revealed that
HuD is upregulated ≈3-fold in miR-375KO islets but down-
regulated in β-Rescue mice to similar levels than WTanimals
(Fig. 2b). Finally, in situ hybridization with miR-375 probes
confirmed restoration of miR-375 expression in the core of
pancreatic islets of β-Rescue mice (Fig. 2c). Together, these
results show that the Tg375 transgene could selectively and
functionally restore endogenous miR-375 expression in β-
cells of miR-375KO mice.
Fig. 1 Metabolic characterization of β-cell-specific miR-375 transgenic
mice. a Relative miR-375 expression in islets and indicated organs of
male wildtype (WT) and Tg375 mice at 12 weeks of age (n=5 for
islets, n=2 for all other tissues). b Relative expression of validated
miR-375 targets in islets of male Tg375 mice and WT controls at
12 week of age. c Body weight of Tg375 (white circles) and WT (black
circles) mice (n=10). dAd libitum-fed blood glucose levels in Tg375 and
control littermate mice (n=10). e Intraperitoneal Glucose Tolerance Test
(IPGTT; 2 g/kg) in overnight fasted Tg375 (white circles) andWT (black
circles) mice at 10 weeks of age (n=11). f Static insulin secretion
performed with 10-week-old control and Tg375 islets (n=5) at
3.3 mmol/l (white bars) and 16.7 mmol/l (black bars) glucose
concentrations. All data shown are mean±s.e.m., except for panel c and
d where s.d. is shown. *p<0.05, **p<0.01
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Metabolic characterization of miR-375KO and β-Rescue
mice revealed no difference in body weight (Fig. 3a) or food
and water intake (data not shown). As expected, miR-375KO
animals developed random fed (Fig. 3b) and fasting hypergly-
cemia (Fig. 3c) from weaning (3 weeks of age) throughout
adult life [10]. Interestingly, β-Rescue mice displayed normal
blood glucose levels in fed and fasting conditions and were
virtually indistinguishable from control mice (Fig. 3b, c).
IPGTT revealed marked glucose intolerance in miR-375KO
animals, whereas β-Rescue mice showed a glucose response
similar toWT littermates (Fig. 3d). Insulin tolerance tests were
similar in WT, Tg375, miR-375KO, and β-Rescue mice, in-
dicating that insulin sensitivity was unchanged (Fig. 3e).
Measurements of insulin excursions in response to glucose
injection showed a profound impairment in insulin secretion
at 15 min after glucose injection in miR-375KO mice (0.55±
0.05 ng/ml in miR-375KO vs 1.30±0.14 ng/ml in WT,
p<0.005), which could be restored to almost WT levels in
Fig. 3 Metabolic characterization
of miR-375 β-Rescue mice. WT,
Tg375, miR-375KO, and β-
Rescue mice were subjected to the
following measurements: a body
weight, b ad libitum-fed blood
glucose levels, c fasting glucose
(6 h and overnight) levels at
12 weeks of age, d IPGTT (2 g/kg)
after an overnight fast at 13 weeks
of age, e ITT (0.75U/kg) after an
overnight fast at 11 weeks of age, f
insulin excursion analysis after an
overnight fast at 16 weeks of age
(3 g/kg). All data shown are
mean±s.e.m; n=6–9; **p<0.01,
***p<0.005 WT vs. miR-375KO,
#p<0.05, ##p<0.01, β-Rescue vs.
miR-375KO
Fig. 2 Functional characterization
ofmiR-375KOmicewith selective
re-expression of miR-375 in
pancreaticβ-cells. aRelative miR-
375 expression in islets of male
WT, Tg375, miR-375KO, and
β-Rescue mice at 12 weeks of age
(n=4–5). Data expressed as fold-
change over WT controls. b
Relative expression of the miR-
375 target HuD in islets of male
WT, Tg375, miR-375KO, and
β-Rescue mice at 12 weeks of age
(n=4–5). c Detection of miR-375
and 28S rRNA in pancreatic tissue
sections from wildtype (WT),
miR-375KO, and β-Rescue mice
using miRNA FISH. Green: miR-
375, Red: 28S rRNA, Blue: cell
nuclei. All data shown are mean±
s.e.m. *p<0.05, ***p<0.005
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β-Rescue mice (1.30±0.14 ng/ml in WT versus 1.08±
0.07 ng/ml in β-Rescue p<0.01) (Fig. 3f). Together, these
findings indicate that selective re-expression of miR-375 in
β-cell of miR-375KO mice is sufficient to restore normal
glycemic control.
To investigate the mechanism by which the miR-375 res-
cue in β-cells of miR-375KO mice improved glucose toler-
ance, we measured pancreatic endocrine function and cell
mass in these mice. Fasting insulin levels were not significant-
ly different between miR-375KO, β-Rescue, Tg375, and WT
control mice (Fig. 4a). As reported previously, we measured a
decrease in pancreatic insulin content in miR-375KO mice,
which was associated with reduced β-cell mass in miR-
375KO mice (Fig. 4b, c) [10]. In contrast, β-Rescue mice
showed partial restoration of pancreatic insulin content and
β-cell mass (Fig. 4b, c). Circulating glucagon levels were
increased ≈4-fold in miR-375KO mice compared to WT con-
trols (Fig. 4d). Interestingly, reconstitution ofmiR-375 expres-
sion in β-cells of miR-375KO mice also decreased plasma
glucagon levels compared to miR-375KO mice (Fig. 4d).
Morphometric analysis revealed partial normalization of α-
cell mass in β-Rescue animals (Fig. 4e). To show that selec-
tive expression of miR-375 in β-cells of miR-375KO mice is
sufficient for the regulation of glucagon signaling in the liver,
pyruvate tolerance was examined in mutant mice. As depicted
in Fig. 4f, miR-375KO mice displayed augmented gluconeo-
genesis, as shown by higher blood glucose levels in response
to a tolerance test (PTT). In contrast,β-Rescue mice displayed
hepatic pyruvate conversion kinetics similar to those of WT
controls. These results indicate thatβ-cell miR-375 deficiency
is the primary cause underlying the phenotype of global miR-
375KOmice and that the increase inα-cell mass and glucagon
secretion arises secondarily to the β-cell defect.
Release of miR-375 from pancreatic β-cells
into circulation
Several studies have suggested that miRNA expressed in β-
cells are also found in the circulation [17]. However, whether
these circulating miRNA indeed originate from β-cells and
not from other organs still remains to be determined. To ad-
dress this, we took advantage of our β-cell-specific miR-375
expressing mouse model to measure the contribution of β-
cells to circulating miR-375 levels in vivo. We first measured
levels of metabolically relevant miRNAs in mouse plasma.
Quantitative PCR analyses revealed that miR-375 and the
broadly expressed miR-16 are both readily detected in the
circulation of C57BL/6 mice (20.8±0.3 Ct, n=3, Fig. 5a). In
addition, we found that liver-enriched miR-122 and miR-192/
194 as well as erythrocyte-enriched miR-451 levels were also
detected in the plasma of these mice (miR-122, 34.69±0.07
Ct; miR-192, 27.06±0.17 Ct; miR-194, 30.48±0.10 Ct; miR-
451, 21.42±−0.16 Ct). Using an absolute quantification, we
found that C56BL/6 mice presented 2×106 miR-375
Fig. 4 Hormone levels and islet cell mass in miR-375 β-Rescue mice.
WT, Tg375, miR-375KO, and β-Rescue mice were subjected to the
following measurements after a 6-h fast: a circulating plasma insulin
levels and b pancreatic insulin content at 24 weeks of age (n=5–6), c
normalized pancreatic α-cell at 5 weeks of age (n=5–7), d plasma
glucagon levels in mice fasted for 3 h at 24 weeks of age (n=5–6), e
pancreaticβ-cell mass at 5 weeks of age (n=3–5), f intraperitoneal PTT in
mice fasted overnight at 15 weeks of age (2 g/kg) (n=6–9). All data
shown are mean±s.e.m; *p<0.05, **p<0.01, ***p<0.005 WT vs.
miR-375KO, #p<0.05, ##p<0.01, ###p<0.005, β-Rescue versus miR-
375KO
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copies/ml of plasma at 7 weeks of age, while that of miR-16
was ≈400-fold higher compared to miR-375 (Fig. 5b). To
determine if plasma miR-375 originates from pancreatic β-
cells, we took advantage of our β-Rescue mouse model
displaying selective expression of endogenousmiR-375 levels
in pancreatic β-cells and performed quantitative measure-
ments in mouse plasma. These studies revealed that plasma
miR-375 levels inβ-Rescue micewere ≈1% compared toWT
littermates. Serum miR-375 levels in miR-375KO mice were
undetectable, thus demonstrating the specificity of the qPCR
assay (Fig. 5c). In contrast, plasma miR-16 levels were not
different between WT, miR-375KO, and β-Rescue animals
(Fig. 5d). These results reveal that a small but significant pro-
portion of circulating miRNAs indeed is derived from pancre-
atic β-cells. To substantiate these findings, we performed
in vitro experiments on pancreatic islets from miR-375KO,
WT and Tg375 mice displaying increasing miR-375 gene
dosage (Fig. 5e). After culture of pancreatic islets for 16 h in
serum-free media, islet supernatants were recovered, centri-
fuged, and miR-375 levels quantified by qPCR. The data in
Fig. 5e show that supernatant miR-375 levels correlate with
islet miR-375 gene dosage. Tg375 islets secreted 1.9±0.45-
fold more miR-375 than WT islets, whereas miR-375 levels
were virtually absent in the supernatant of miR-375KO islets
(Fig. 5e). Together, these results indicate that the β-cell-
enriched miR-375 is secreted from pancreatic islets, but
miRNA release from this organ contributes only a small frac-
tion to the overall blood levels in mice.
Increased plasma levels of miR-375 in response to β-cell
destruction
Since our findings indicate that circulating miRNAs are re-
leased from β-cells, we hypothesized that their levels may
correlate with β-cell mass and may serve as a biomarker of
β-cell viability in diabetes. To investigate this, we employed
different models of β-cell stress: an acute β-cell toxicity mod-
el induced by treating mice with STZ (150 mg/kg), obesity
mouse models displaying normoglycemia due to increased β-
cell proliferation, function and pancreatic insulin content (i.e.,
dietary (HFD), and genetic (ob/ob mice on C57BL/6N back-
ground) [3, 22, 23], as well as diabetic models (db/dbmice on
BLKS background) exhibiting profound hyperglycemia, re-
duced plasma insulin levels due to β-cell dysfunction [24,
25] and apoptosis [26, 27]. For the acute toxicity model, blood
was analyzed for glucose and serum miRNAs levels 3 days
after STZ injection. STZ treatment resulted in elevation of
blood glucose levels, which correlated with depletion of β-
cells as revealed by pancreatic insulin content measurements
(Fig. 6a, b). We observed that circulating miR-375 levels were
Fig. 5 Pancreatic islets secrete miR-375 in the circulation. aDetection of
miRNAs in C57BL/6 mouse plasma. Shown is the mean Ct value of
indicated miRNAs evaluated by qPCR after 45 cycles (n=3). b Copy
number of circulating miR-375 and miR-16 in C57BL/6 mice at
7 weeks. c, d miR-375 copy number per ml of plasma of wildtype
(WT), Tg375, miR-375KO, and β-Rescue mice at 20 weeks of age. e
Relative miR-375 levels in supernatant of pancreatic islets isolated from
WT, miR-375KO, and Tg375 mice cultured in serum-free media for 16 h
at 37 °C. Media, serves as a negative control (n=3). Data expressed as
fold-change overWTcontrols. All data shown are mean±s.e.m; *p<0.05,
***p<0.005
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increased by ≈2-fold in STZ-treated diabetic mice as com-
pared to controls (Fig. 6c), while those of miR-16, a ubiqui-
tously expressed miRNA was unaffected by STZ treatment
(Fig. 6d). Interestingly, increased plasma miR-375 levels were
also measured in hyperglycemic BKS.db/db mice compared
to control littermates, whereas miR-16 levels were similar
(Fig. 6e–g). In contrast, our analysis revealed that miR-375
levels were decreased by ≈50 and 20 % in islets of
normoglycemic HFD and ob/ob mice compared to lean litter-
mate controls, respectively (Fig. 6h–k). Together, these results
indicate that miR-375 levels in the circulation do not correlate
withβ-cell function ormass but may be a surrogate marker for
β-cell injury and cell death.
Lastly, we extended our findings to diabetic patients and
measured circulating miR-375 levels in human subjects with
inactivating mutations in HNF1α (maturity-onset of the
young, type 3 (MODY3)), T2D, T1D, and healthy subjects
(no diagnosed metabolic disease (NDMD)). This analysis re-
vealed that circulating miR-375 levels were unaltered in
MODY3 and T2D but elevated in T1D subjects compared to
healthy controls (Fig. 6l). Although not reaching statis-
tical significance due to reduced patient number, we
observed an overall trend toward higher levels in both
genders (NDMD males 6.9×106±0.9×106 copies/ml and
T1D males 9.6×106±1.7×106 copies/ml n=16–23; NDMD
females 6.8×106±0.9×106 copies/ml; T1D females 12.5×
106±2.7×106, n=22–28). Together, these results indicate that
plasma miR-375 levels do not discriminate between different
forms of T2D but may be used as an indicator of acute β-cell
destruction and autoimmune diabetes.
Discussion
Previous work from our group revealed that miR-375 is re-
quired for maintenance of α- and β-cell mass in mice [10].
Using genetic loss of function experiments, we found that
genetic inactivation of miR-375 decreases β-cell mass but
concomitantly increases α-cell mass. We now report the gen-
eration of a miR-375 gain-of-function mouse model with
Fig. 6 Correlation between
circulating miR-375 levels and
β-cell injury. a Blood glucose
levels and b pancreatic insulin
content in 6-h fasted C57BL/6
(10-week-old) after 72 h
treatment with streptozotocin
(STZ, 1×150 mg/kg) (n=7–8). c
Circulating miR-375 and d miR-
16 copy number in plasma of 6-h
fasted C57BL/6 WT mice (10-
week-old) after being injected
with STZ (+, 1×150 mg/kg) or
PBS as control (−) for 3 days
(n=7–8). e Blood glucose and f
circulating miR-375 and g miR-
16 levels in WT and db/db (BKS-
background) male mice at
8 weeks of age (n=4–5). h Blood
glucose, i pancreatic insulin
content, and j circulating miR-
375 and k miR-16 in C57BL/6
(WT) mice fed a normal or high-
fat diet (HFD, for 25 weeks) and
ob/ob (C57BL/6 background)
mice (23-week-old) (n=5). l
Circulating miR-375 levels in
healthy or no diagnosed
metabolic disease patients
(n=51), HNF1α/MODY3
mutation carriers (n=47), T1D
(n=38) and T2D (n=58). All data
shown are mean±s.e.m; *p<0.05,
**p<0.01, ***p<0.005
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selective overexpression of miR-375 in pancreaticβ-cells. We
initially hypothesized that Tg375 mice would present im-
proved metabolic functions associated with an increase in β-
cell mass. Surprisingly, we did not observe any changes in
islet endocrine cell mass, pancreatic β-cell function, and gly-
cemic control in Tg375 mice. This could be explained by the
high endogenous miR-375 levels in pancreatic islets of both
mouse and human [7, 10, 28], where miR-375 mRNA targets
regulating β-cell homeostasis are fully engaged and repressed
by this miRNA. Therefore, any further increase in miR-375
levels is unlikely to influence target expression. For example,
the levels of HuD mRNA are unchanged in Tg375 islets but
found at higher levels in miR-375KO islets (Figs. 1 and 2).
However, when islet miR-375 gene dosage is decreased in
islets of Tg375 through inactivation of endogenous alleles of
the miRNA (β–Rescue mice), the repressive action of miR-
375 on HuDmRNA is recovered. These results support recent
quantitative studies showing that miRNA activity is deter-
mined by a delicate balance between miRNA and mRNA
target abundance [29]. Therefore, the protective role of miR-
375 overexpression on β cell growth might become more
important in models of pancreatic β-cells failure where loss
of β-cell function represents the main driving force of meta-
bolic dysfunction. Thus, therapeutic approaches aimed at in-
creasing β-cell growth and proliferation through upregulation
of miR-375 function should be considered only in a setting of
reduced miR-375 levels.
To assess the relative importance of α- and β-cell mass
remodeling for the overall phenotype of global miR-375KO
mice, we conducted genetic rescue experiments using Tg375
mice and global miR-375KO mice (Fig. 3). Crossing of both
mouse lines allowed us to generate mice expressing miR-375
exclusively in pancreatic β-cells. Interestingly, these β-
Rescue mice were indistinguishable from wildtype animals
in several aspects, including: (1) miR-375 levels in islet, (2)
insulin and glucagon levels, (3) glucose, insulin and pyruvate
tolerance, and (4) α- and β-cell mass (Figs. 3 and 4). These
data indicate that the primary defect of global miR-375KO
mice is caused by the loss of miR-375 in pancreatic β-cells,
which results in a secondary and indirect α-cell growth and
proliferative response. The low hypothalamic expression de-
tected in Tg375 mice is unlikely to be responsible for the β-
cell rescue phenotype since insulin secretion and glucose tol-
erance is indistinguishable fromWTanimals. It was previous-
ly shown that β-cell destruction by low doses of STZ leads to
α-cell hyperplasia, partially phenocopying theβ-cell hypopla-
sia and α-cell hyperplasia of miR-375KO mice [10, 30]. The
genetic rescue experiment further demonstrates that the con-
tent of miR-375 in β-cells can indirectly influence the func-
tion and growth of α-cells. For instance, insulin is known to
inhibit glucagon secretion, and the increased β-cell mass and
function in β-Rescue mice might contribute to the reduced
glucagon levels in these mice [31]. Direct genetic evidence
for a role of β-cell derived insulin in the modulation of α-cell
responses was provided by Kawamori et al. who demonstrated
that insulin binding to its receptor on α-cells modulates gluca-
gon secretion (but not α-cell mass), a coupling that is lost in
obesity-induced insulin resistance and that contributes to the
hyperglucagonemia measured in patients with T2D [32–34].
Recent reports have revealed that circulating miRNA ex-
pression is altered in pathological settings and may be used as
biomarkers. Previous studies reported that miR-375 levels
correlate with advanced prostate [35] and hepatocellular car-
cinoma [36] in humans and revealed to be among the most
highly differentially regulated blood miRNAs in apoE-
deficient mice [14]. These studies are difficult to reconcile
considering the selective expression of miR-375 in neuroen-
docrine organs [6] and intestinal goblet cells [37] and may
indicate that metabolic effects influence the secretion, clear-
ance, or stability of miR-375. We now provide the first evi-
dence for secretion of miR-375 by pancreatic β-cells in vivo
in unstressed conditions (Fig. 5). Circulating miR-375 levels
in mice exclusively expressing miR-375 in β-cells
corresponded to approximately 1 % of WT mice. This indi-
cates that although β-cells contribute to the circulating levels
of miR-375, most of the miRNA originates from other organs,
most likely neuroendocrine cells from lung, gastrointestinal
tract, thyroid, and adrenals. We found increased circulating
miR-375 levels in response to acute pancreatic β-cell injury
induced by STZ, indicating that acute β-cell death can result
in increased circulating miR-375 levels. These data are in
accordance with Erener et al. reporting increased miR-375
levels in STZ-treated and NOD mice and islets [18]. In agree-
ment with this study, we also found increased circulating miR-
375 levels in a mouse model of BKS-db/db mice that display
β-cell apoptosis and profound hyperglycemia. In contrast,
plasma miR-375 levels were reduced in two normoglycemic
models of obesity (HFD and ob/ob on C57BL/6 background)
with increased pancreatic β-cell function, proliferation and
absence of apoptosis. This reduction in plasmamiR-375 levels
may be due to increased renal clearance, since miRNAs are
secreted in the urine, and body weight is positively correlated
with glomerular filtration rate [38, 39], and an inverse corre-
lation exists betweenmiRNAs abundance and kidney function
[40]. This may also explain why miR-375 levels were not
significantly increased in our T2D cohort in contrast to what
was recently reported by Higuchi et al. where patients exhibits
a much higher BMI (31.6) than the cohort we analyzed
(BMI=25.9) [41]. It will therefore be interesting to measure
miR-375 urinary excretion in obese and non-obese subjects
with normal and impaired glucose tolerance. Plasma miR-375
therefore is unlikely to serve as a marker of altered β-cell
function, a notion also supported by the similar plasma miR-
375 levels in subjects with MODY3 that is known to exhibit
β-cell dysfunction. Importantly, our quantitative finding that
release of miR-375 from living β-cells in vivo only
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contributes a very small fraction to the total plasma levels
offers a rational explanation why changes in β-cell function
and mass are insufficient to translate into measurable alter-
ations in miR-375 plasma levels.
While diagnostic approaches for T1D have been devel-
oped, there is a need to identify novel predictive molecules
to identify and monitor disease progression with greater accu-
racy. To our surprise, our data indicate that circulating miR-
375 levels are increased in human T1D. Considering the small
contribution of β-cells to miR-375 levels in the blood, we
believe that the most likely explanation for this observation
is that hyperglycemia per se elicits increased miR-375 secre-
tion from tissues other than pancreatic β-cells. Alternatively,
increased miR-375 levels in the plasma of T1D may result in
reduced renal clearance, a notion that is supported by the
correlation of urinary miR-21 levels with the rate of kidney
function decline and risk of progression to dialysis-dependent
kidney failure [40, 42]. Lastly, it is possible that continuous
autoimmune destruction and regeneration of β-cells in T1D
may contribute to increased plasma miR-375 levels. This is
further supported by plasmamiRNA profiling in children with
newly diagnosed T1D that revealed elevated levels of twelve
highly expressed miRNAs [43]. Increased α-cell mass ob-
served in human T1D patients could also contribute to the
elevated miR-375 levels in the circulation in the absence of
β-cells [44–46].
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